Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
Holding XOMA?
Track your performance easily
XOMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.48 - $27.36
Previous Close$27
Volume26.06K
Average Volume (3M)17.60K
Market Cap
$314.24M
Enterprise Value$285.24M
Total Cash (Recent Filing)$153.45M
Total Debt (Recent Filing)$124.45M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Aug 06, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding11,638,553
10 Day Avg. Volume17,345
30 Day Avg. Volume17,598
Standard Deviation0.16
R-Squared0.07
Alpha0.00789
Financial Highlights & Ratios
Price to Book (P/B)3.26
Price to Sales (P/S)59.81
Price to Cash Flow (P/CF)-18.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue59.95
Enterprise Value/Gross Profit59.95
Enterprise Value/Ebitda-7.01
Forecast
1Y Price Target
$74.00Price Target Upside174.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Xoma News
PremiumPress Releases
XOMA Declares Quarterly Preferred Stock Dividends
Bulls Say, Bears Say
Bulls Say
Portfolio ExpansionXOMA continues to impress with its capital deployment strategies, finding both classical and creative ways to add to its royalty aggregator portfolio.
Product ApprovalThe FDA has approved the Vabysmo prefilled ready-to-use syringe for wet-AMD, DME, and RVO, simplifying physician administration.
Revenue GrowthPartner Roche's 1Q24 results showed continued strength of Vabysmo, providing an important and growing royalty stream to XOMA with a revenue increase of 96.1%.
Bears Say
Agreement ObligationsIf the aggregated payments received by XOMA exceed $88M, XOMA will pay $11M to Daré for each successive $22M XOMA receives under the agreement.
Financial PerformanceThe company's operating loss was $7M, which was slightly higher than the estimated $6M.
Royalty RatesIf XOMA receives more than $110M under the agreement, the royalty rate on Ovaprene and sildenafil cream will decrease to 2.5% and 1.5%, respectively.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $13.48 and its highest was $27.36 in the past 12 months.
What is Xoma Corp’s market cap?
Currently, no data Available
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Aug 06, 2024 which is 45 days ago.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on May 09, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.15.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -$0.26.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 11,638,553 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went down -2.107%.
Which hedge fund is a major shareholder of Xoma Corp?
Among the largest hedge funds holding Xoma Corp’s share is Woodline Partners LP. It holds Xoma Corp’s shares valued at 2M.
---
Xoma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.00 (174.38% Upside)
$74.00 (174.38% Upside)
Hedge Fund Trend
Increased
By 21.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.96%
12-Months-Change
Fundamentals
Return on Equity
-40.24%
Trailing 12-Months
Asset Growth
64.16%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
---
XOMA Stock 12 Month Forecast
Average Price Target
$74.00
▲(174.38% Upside)
Technical Analysis
Best Analysts Covering XOMA
1 Year
1 Year Success Rate
13/13 ratings generated profit
1 Year Average Return
+35.42%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.42% per trade.
---